Design, Synthesis and Anticancer Activity of New Polycyclic: Imidazole, Thiazine, Oxathiine, Pyrrolo-Quinoxaline and Thienotriazolopyrimidine Derivatives
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
A Remarkable Case of Pterin Specific Oxidative Coupling: Unequivocal
Tetrahedron Letters 57 (2016) 3277–3280 Contents lists available at ScienceDirect Tetrahedron Letters journal homepage: www.elsevier.com/locate/tetlet A remarkable case of pterin specific oxidative coupling: unequivocal synthesis of 6,7-alkoxypterins and 1,4-dioxanopterin with ceric ammonium nitrate ⇑ Manas Kumar Das a, Shyamaprosad Goswami a, , Ching Kheng Quah b, Hoong-Kun Fun b,c a Department of Chemistry, Indian Institute of Engineering and Science Technology, Shibpur, Howrah 711103, West Bengal, India b X-ray Crystallography Unit, School of Physics, Universiti Sains Malaysia, 11800 USM, Penang, Malaysia c Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box. 2457, Riyadh 11451, Saudi Arabia article info abstract Article history: A facile and efficient synthesis of a series of methoxy and ethoxy substituted pterins (characterized by Received 3 May 2016 single crystal X-ray structures of 6,7-dimethoxy and diethoxy-pterins) along with 1,4-dioxanopterin is Revised 6 June 2016 reported along with a possible mechanism for their formation by treatment of pterins with ceric ammo- Accepted 8 June 2016 nium nitrate in methanol, ethanol, and ethylene glycol respectively. This unequivocal alkoxylation is Available online 16 June 2016 unique only with pterin (and 5-deaza-pterin) and is unsuccessful with quinoxaline. Ó 2016 Elsevier Ltd. All rights reserved. Keywords: Alkoxy pterin 1,4-Dioxano pterin Ceric ammonium nitrate Ethylene glycol Introduction O O (NH4)2Ce(NO3)6 N (4-5 equiv), ROH N OR O HN O HN Pterins are among the more important substructures in hetero- reflux, 2-3 h cycles, and their versatile properties make them more interesting N N N R=Me,Et N N N OR H H than other heterocycles such as quinoxalines, pyridines, pyrimidi- O nes etc.1 It is also known that the derivatives of pterin mainly (NH4)2Ce(NO3)6 N O (4-5 equiv), OH(CH2)2OH O HN include pterins and folates. -
Investigating the Effect of the 2-Substituent
molecules Communication Nucleophilic Substitution on 2-Monosubstituted Quinoxalines Giving 2,3-Disubstituted Quinoxalines: Investigating the Effect of the 2-Substituent Ndumiso Thamsanqa Ndlovu and Winston Nxumalo * Department of Chemistry, Faculty of Science and Agriculture, University of Limpopo, Private Bag X 1106, Sovenga 0727, South Africa; [email protected] * Correspondence: [email protected]; Tel.: +27-015-268-2331 Academic Editor: Philippe Belmont Received: 30 August 2016; Accepted: 23 September 2016; Published: 30 September 2016 Abstract: An investigation on the effect of substituent at the 2-position of mono-substituted quinoxalines in the synthesis of di-substituted quinoxaline derivatives via nucleophilic substitution reactions, is reported. Di-substituted quinoxalines bearing aryl-alky, aryl-aryl, aryl-heteroaryl, aryl-alkynyl, and amino-alkyl substituents were prepared in moderate to good yields. 2-Monosubstituted quinoxalines bearing a phenyl and butyl substituent reacted readily with alkyl-, aryl-, heteroaryl- and alkynyl- nucluephiles, giving di-substituted quinoxalines. 2-Monosubstituted quinoxalines bearing an amine and alkynyl substituent only reacted with alkyl nucleophiles. Oxidative rearomatization to give 2,3-disubstituted quinoxaline products occurred in atmospheric O2. Keywords: 2,3-disubsituted quinoxaline; nucleophilic substitution; oxidative rearomatization 1. Introduction Quinoxaline derivatives possess extensive applications in medicinal chemistry, due to their broad spectrum of biological activity [1,2]. A large number of synthetic quinoxalines have been reported to exhibit anti-tubercular [3], anti-viral [4,5], anti-microbial [6,7], and neuroprotective [8,9] activity. Quinoxaline derivatives have been reported to be prepared, but not limited, by intramolecular cyclisation of N-substituted aromatic ortho-diamines [10], ring transformation of benzofurazans [11], and condensation of benzofuran-1-oxide to form quinoxaline-N-oxides [12]. -
Electrooxidation Enables Highly Regioselective Dearomative Annulation of Indole and Benzofuran Derivatives
ARTICLE https://doi.org/10.1038/s41467-019-13829-4 OPEN Electrooxidation enables highly regioselective dearomative annulation of indole and benzofuran derivatives Kun Liu1, Wenxu Song1, Yuqi Deng1, Huiyue Yang1, Chunlan Song1, Takfaoui Abdelilah1, Shengchun Wang 1, Hengjiang Cong 1, Shan Tang1 & Aiwen Lei1* 1234567890():,; The dearomatization of arenes represents a powerful synthetic methodology to provide three-dimensional chemicals of high added value. Here we report a general and practical protocol for regioselective dearomative annulation of indole and benzofuran derivatives in an electrochemical way. Under undivided electrolytic conditions, a series of highly functio- nalized five to eight-membered heterocycle-2,3-fused indolines and dihydrobenzofurans, which are typically unattainable under thermal conditions, can be successfully accessed in high yield with excellent regio- and stereo-selectivity. This transformation can also tolerate a wide range of functional groups and achieve good efficiency in large-scale synthesis under oxidant-free conditions. In addition, cyclic voltammetry, electron paramagnetic resonance (EPR) and kinetic studies indicate that the dehydrogenative dearomatization annulations arise from the anodic oxidation of indole into indole radical cation, and this process is the rate- determining step. 1 College of Chemistry and Molecular Sciences, Institute for Advanced Studies (IAS), Wuhan University, Wuhan 430072, P. R. China. *email: aiwenlei@whu. edu.cn NATURE COMMUNICATIONS | (2020) 11:3 | https://doi.org/10.1038/s41467-019-13829-4 | www.nature.com/naturecommunications 1 ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13829-4 reaking the aromatic systems of electron-rich arenes or fused indolines (Fig. 1a)39–44. Therefore, it is highly appealing to heteroarenes provides three-dimensional chemicals of high develop efficient approaches to allow for their preparation. -
)&F1y3x PHARMACEUTICAL APPENDIX to THE
)&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE -
Pharmaceutical Appendix to the Harmonized Tariff Schedule
Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. -
Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01 -
(12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin Et Al
USOO8486374B2 (12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin et al. (45) Date of Patent: Jul. 16, 2013 (54) HYDROPHILIC, NON-AQUEOUS (56) References Cited PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES U.S. PATENT DOCUMENTS 1,159,250 A 11/1915 Moulton 1,666,684 A 4, 1928 Carstens (75) Inventors: Dov Tamarkin, Maccabim (IL); Meir 1924,972 A 8, 1933 Beckert Eini, Ness Ziona (IL); Doron Friedman, 2,085,733. A T. 1937 Bird Karmei Yosef (IL); Alex Besonov, 2,390,921 A 12, 1945 Clark Rehovot (IL); David Schuz. Moshav 2,524,590 A 10, 1950 Boe Gimzu (IL); Tal Berman, Rishon 2,586.287 A 2/1952 Apperson 2,617,754 A 1 1/1952 Neely LeZiyyon (IL); Jorge Danziger, Rishom 2,767,712 A 10, 1956 Waterman LeZion (IL); Rita Keynan, Rehovot (IL); 2.968,628 A 1/1961 Reed Ella Zlatkis, Rehovot (IL) 3,004,894 A 10/1961 Johnson et al. 3,062,715 A 11/1962 Reese et al. 3,067,784. A 12/1962 Gorman (73) Assignee: Foamix Ltd., Rehovot (IL) 3,092.255. A 6, 1963 Hohman 3,092,555 A 6, 1963 Horn 3,141,821 A 7, 1964 Compeau (*) Notice: Subject to any disclaimer, the term of this 3,142,420 A 7/1964 Gawthrop patent is extended or adjusted under 35 3,144,386 A 8/1964 Brightenback U.S.C. 154(b) by 1180 days. 3,149,543 A 9, 1964 Naab 3,154,075 A 10, 1964 Weckesser 3,178,352 A 4, 1965 Erickson (21) Appl. -
European Surveillance of Healthcare-Associated Infections in Intensive Care Units
TECHNICAL DOCUMENT European surveillance of healthcare-associated infections in intensive care units HAI-Net ICU protocol Protocol version 1.02 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT European surveillance of healthcare- associated infections in intensive care units HAI-Net ICU protocol, version 1.02 This technical document of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Carl Suetens. In accordance with the Staff Regulations for Officials and Conditions of Employment of Other Servants of the European Union and the ECDC Independence Policy, ECDC staff members shall not, in the performance of their duties, deal with a matter in which, directly or indirectly, they have any personal interest such as to impair their independence. This is version 1.02 of the HAI-Net ICU protocol. Differences between versions 1.01 (December 2010) and 1.02 are purely editorial. Suggested citation: European Centre for Disease Prevention and Control. European surveillance of healthcare- associated infections in intensive care units – HAI-Net ICU protocol, version 1.02. Stockholm: ECDC; 2015. Stockholm, March 2015 ISBN 978-92-9193-627-4 doi 10.2900/371526 Catalogue number TQ-04-15-186-EN-N © European Centre for Disease Prevention and Control, 2015 Reproduction is authorised, provided the source is acknowledged. TECHNICAL DOCUMENT HAI-Net ICU protocol, version 1.02 Table of contents Abbreviations ............................................................................................................................................... -
(12) Patent Application Publication (10) Pub. No.: US 2014/0271923 A1 Reid (43) Pub
US 20140271923A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0271923 A1 Reid (43) Pub. Date: Sep. 18, 2014 (54) COMPOSITIONS & FORMULATIONS FOR (52) U.S. Cl. PREVENTING AND TREATING CHRONIC CPC ............. A6 IK3I/122 (2013.01); A61 K38/063 DISEASES THAT CLUSTER IN PATIENTS (2013.01); A61 K3I/496 (2013.01); A61 K SUCH AS CARDIOVASCULAR DISEASE, 45/06 (2013.01); A61 K31/4164 (2013.01); DLABETES, OBESITY, POLYCYSTIC OVARY A61K 31/12 (2013.01); A61 K3I/375 SYNDROME, HYPERLIPIDEMIA AND (2013.01); A61 K3I/355 (2013.01) HYPERTENSION, ASWELLAS FOR USPC ..... 424/651: 514/690: 514/21.9; 514/254.07; PREVENTING AND TREATING OTHER 514/383: 514/365: 514/256; 514/398: DISEASES AND CONDITIONS 514/236.2: 514/314: 514/154: 514/311; 514/31; 514/77; 514/39; 514/275; 514/253.08 (71) Applicant: Christopher Brian Reid, Los Angeles, CA (US) (57) ABSTRACT Patients inflicted with various clustering chronic diseases (72) Inventor: Christopher Brian Reid, Los Angeles, require treatment with multiple drugs having distinct mecha CA (US) nisms of action. Accordingly, patients with multiple condi tions suffer from cumulative side effects of multiple drugs as (21) Appl. No.: 13/815,664 well as drug-drug interactions. Embodiments, agents, com pounds or drugs of the present invention, such as sesquiter (22) Filed: Mar 14, 2013 penes, e.g., Zerumbone, replace an equal or larger number of approved drugs during patient treatment. Examples of disor Publication Classification ders prevented or ameliorated by administration of the for mulations of this invention include but are not limited to (51) Int. -
Recent Trends in Synthesis of Quinoxaline and Its Derivatives *Dinesh Bharagava1 and Dr
Dinesh Bharagava et al. / Journal of Pharmacy Research 2012,5(1),130-134 Review Article Available online through ISSN: 0974-6943 http://jprsolutions.info Recent trends in synthesis of quinoxaline and its derivatives *Dinesh Bharagava1 and Dr. Gopal Garg2 1Shekhawati College of Pharmacy, Dundlod, District-Jhunjhunu (Raj.) India 2VNS Institute of Pharmacy, Bhopal (M.P.) India Received on:20-09-2011; Revised on: 15-10-2011; Accepted on:10-12-2011 ABSTRACT Quinoxaline is nitrogen containing heterocyclic nucleus made up of benzene ring and pyrazine ring. It is a wonderful nucleus which gives almost all type of biological activity. So due to diversity in biological activity, it attracts the researchers to find out more its biological activity. But its traditional synthesis suffers from variety of disadvantage such as pollution, high cost, low yield, tedious work-up and long reaction time. Recently different methods have been developed for synthesis of quinoxaline derivatives by use of microwave and catalyst. In present study, we provide a concise review on history, chemistry, different methods of quinoxaline synthesis and its biological activity. Key words: Quinoxaline, o-Phenylenediamine, Diketones, Benzopyrazine, Quinoxalin-2-one INTRODUCTION 1 2. HISTORY 8 N N Quinoxaline is heterocyclic compound containing benzene ring and pyrazine 8 a 2 7 ring. Pyrazine is water soluble and stable colourless compound. In quinoxaline, benzene ring is fused with diazines compounds. The pyrazine ring system is present in the fungal metabolite aspergillic acid and also in luciferin. Methoxy 6 3 4 a pyrazine are essential component of aroma of many fruits and vegetables such N N 5 4 as capsicum and peas [32]. -
Recent Advances in the Synthesis of Benzimidazol (On) Es Via Rearrangements of Quinoxalin (On) Es
RSC Advances View Article Online REVIEW View Journal | View Issue Recent advances in the synthesis of benzimidazol(on)es via rearrangements of Cite this: RSC Adv.,2016,6,42132 quinoxalin(on)es Vakhid A. Mamedov* This is the first review describing all the quinoxaline–benzimidazole rearrangements as a whole and the new quinoxalinone–benzimidazol(on)e rearrangements in particular when exposed to nucleophilic rearrangements for the synthesis of various biheterocyclic motifs. The scope of the rearrangements is Received 12th February 2016 illustrated by way of numerous examples of their application, and in doing so, the review contains over Accepted 2nd April 2016 131 references and covers all of the literature, from the first report of the rearrangement of 2,3- DOI: 10.1039/c6ra03907c diphenylquinoxaline by Ogg and Bergstrom in 1931 up to more recent examples in the past few years. www.rsc.org/advances The mechanisms for the selected transformations are also discussed. Creative Commons Attribution 3.0 Unported Licence. 1 Introduction its medicinal importance. The benzimidazole scaffold acts as an important class of heterocyclic compounds with a wide range of Benzimidazole, rstly described by Hobrecker in 1872,1 is an biological properties.6 Benzimidazole derivatives are structural important privileged heterocyclic motif2–5 and one of the most isosteres of naturally occurring nucleotides, which allow them widely investigated scaffolds by synthetic chemists because of to easily interact with the biopolymers of the living systems and different kinds of biological activity have been obtained. 2- Aminobenzimidazoles proved useful for acid/base catalysis and A. E. Arbuzov Institute of Organic and Physical Chemistry, Kazan Scientic Center of can substitute guanidinium groups in receptor molecules the Russian Academy of Sciences, Arbuzov str. -
Essentials of Heterocyclic Chemistry-I Heterocyclic Chemistry
Baran, Richter Essentials of Heterocyclic Chemistry-I Heterocyclic Chemistry 5 4 Deprotonation of N–H, Deprotonation of C–H, Deprotonation of Conjugate Acid 3 4 3 4 5 4 3 5 6 6 3 3 4 6 2 2 N 4 4 3 4 3 4 3 3 5 5 2 3 5 4 N HN 5 2 N N 7 2 7 N N 5 2 5 2 7 2 2 1 1 N NH H H 8 1 8 N 6 4 N 5 1 2 6 3 4 N 1 6 3 1 8 N 2-Pyrazoline Pyrazolidine H N 9 1 1 5 N 1 Quinazoline N 7 7 H Cinnoline 1 Pyrrolidine H 2 5 2 5 4 5 4 4 Isoindole 3H-Indole 6 Pyrazole N 3 4 Pyrimidine N pK : 11.3,44 Carbazole N 1 6 6 3 N 3 5 1 a N N 3 5 H 4 7 H pKa: 19.8, 35.9 N N pKa: 1.3 pKa: 19.9 8 3 Pyrrole 1 5 7 2 7 N 2 3 4 3 4 3 4 7 Indole 2 N 6 2 6 2 N N pK : 23.0, 39.5 2 8 1 8 1 N N a 6 pKa: 21.0, 38.1 1 1 2 5 2 5 2 5 6 N N 1 4 Pteridine 4 4 7 Phthalazine 1,2,4-Triazine 1,3,5-Triazine N 1 N 1 N 1 5 3 H N H H 3 5 pK : <0 pK : <0 3 5 Indoline H a a 3-Pyrroline 2H-Pyrrole 2-Pyrroline Indolizine 4 5 4 4 pKa: 4.9 2 6 N N 4 5 6 3 N 6 N 3 5 6 3 N 5 2 N 1 3 7 2 1 4 4 3 4 3 4 3 4 3 3 N 4 4 2 6 5 5 5 Pyrazine 7 2 6 Pyridazine 2 3 5 3 5 N 2 8 N 1 2 2 1 8 N 2 5 O 2 5 pKa: 0.6 H 1 1 N10 9 7 H pKa: 2.3 O 6 6 2 6 2 6 6 S Piperazine 1 O 1 O S 1 1 Quinoxaline 1H-Indazole 7 7 1 1 O1 7 Phenazine Furan Thiophene Benzofuran Isobenzofuran 2H-Pyran 4H-Pyran Benzo[b]thiophene Effects of Substitution on Pyridine Basicity: pKa: 35.6 pKa: 33.0 pKa: 33.2 pKa: 32.4 t 4 Me Bu NH2 NHAc OMe SMe Cl Ph vinyl CN NO2 CH(OH)2 4 8 5 4 9 1 3 2-position 6.0 5.8 6.9 4.1 3.3 3.6 0.7 4.5 4.8 –0.3 –2.6 3.8 6 3 3 5 7 4 8 2 3 5 2 3-position 5.7 5.9 6.1 4.5 4.9 4.4 2.8 4.8 4.8 1.4 0.6 3.8 4 2 6 7 7 3 N2 N 1 4-position